This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Katz, M. H. Articles by Hoffman, R. M. Search for Related Content PubMed PubMed Citation Articles by Katz, M. H. Articles by Hoffman, R. M.

Survival Efficacy of Adjuvant Cytosine-Analogue CS-682 in a Fluorescent Orthotopic Model of Human Pancreatic Cancer

¹ Department of Surgery, University of California at San Diego, San Diego, California, and ² AntiCancer, Inc., San Diego, California

Adjuvant treatment with the cytosine analogue 1-(2-C-cyano-2-deoxy-ß-D-arabino-pentofuranosyl)-N⁴-palmitoylcytosine (CS-682) results in a highly significant increase in survival in the aggressive orthotopic MIA-PaCa-2 human pancreatic cancer mouse model. Seven days after implantation, mice were randomized into eight groups, depending on whether they were to be treated by tumor resection, 5 weeks of CS-682 chemotherapy at 40–60 mg/kg once daily, or both. Throughout the course of treatment, noninvasive optical whole-body imaging based on brilliant red fluorescent protein expression of the tumor permitted visualization and quantification of primary, metastatic, and recurrent disease. Total tumor burden negatively correlated with survival. Untreated mice died of disseminated disease with a median survival of 26 days. Surgical resection alone conferred a small but significant survival advantage (median survival, 28 days, P = 0.03). Primary CS-682 treatment at all doses also significantly prolonged survival compared with untreated animals (P < 0.05) and was more effective than surgery alone at doses of 50 and 60 mg/kg (median survival, 34 days, P = 0.045, and 38.5 days, P = 0.03, respectively). Maximal survival (median, 48 days, with 30% of animals surviving longer than 60 days) was achieved by adjuvant CS-682 (50 mg/kg), given after surgical resection of the primary pancreatic tumor (P = 0.004 compared with surgery alone). The results demonstrate that adjuvant oral administration of CS-682 for pancreatic cancer is highly effective with acceptable toxicity, suggesting its potential for cure of this disease in appropriate combinations.

This article has been cited by other articles:

				Z. Tong, A. B. Kunnumakkara, H. Wang, Y. Matsuo, P. Diagaradjane, K. B. Harikumar, V. Ramachandran, B. Sung, A. Chakraborty, R. S. Bresalier, et al. Neutrophil Gelatinase-Associated Lipocalin: A Novel Suppressor of Invasion and Angiogenesis in Pancreatic Cancer Cancer Res., August 1, 2008; 68(15): 6100 - 6108. [Abstract] [Full Text] [PDF]

				M. Yang, P. Jiang, and R. M. Hoffman Whole-Body Subcellular Multicolor Imaging of Tumor-Host Interaction and Drug Response in Real Time Cancer Res., June 1, 2007; 67(11): 5195 - 5200. [Abstract] [Full Text] [PDF]